Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy
- Conditions
- Myopia
- Interventions
- Drug: Combination therapy "IVB + rf-PDT"
- Registration Number
- NCT00802126
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Brief Summary
The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.
- Detailed Description
In this retrospective interventional case series, 16 patients with myopic CNV were included. All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later. All patients were previously treated with IVB monotherapy and active leaking of CNV occurred 90 to 120 days after the treatment.
Best-corrected visual acuity (BCVA-ETDRS), foveal thickness (FT) on optical coherence tomography (OCT), and fluorescein and indocyanine green angiographic (FA; ICG) findings were recorded. Follow-up evaluations were carried out for 12 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
- Myopic CNV, CNV leakage
- CNV not associated with high myopia
- No activity of CNV
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bevacizumab and verteporfin Combination therapy "IVB + rf-PDT" -
- Primary Outcome Measures
Name Time Method BCVA improved 6 months
- Secondary Outcome Measures
Name Time Method no CNV leakage 6 months
Trial Locations
- Locations (1)
Ophthalmology Department SUN
🇮🇹Napoli, Italy